10-K: Envoy Medical Reports Losses, Going Concern Doubt Amid CI Trial Progress

Envoy Medical, Inc. reported a significant net loss and accumulated deficit for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, despite fully enrolling its pivotal clinical trial for the Acclaim CI.

Summary

• Envoy Medical, Inc. (COCH) reported a net loss of $23.8 million for the fiscal year ended December 31, 2025, an increase from $20.8 million in 2024.
• The company's accumulated deficit reached $313.4 million as of December 31, 2025, up from $284.7 million in 2024.
• Management's independent registered accounting firm included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• The pivotal clinical study for the Acclaim CI, a fully implanted cochlear implant, completed enrollment of all 56 patients on March 10, 2026.
• FDA approval for the Acclaim CI is anticipated in late 2027 or early 2028, contingent on successful clinical trial results and regulatory review.
• The company successfully completed a public offering in February 2026, raising approximately $27.7 million in net proceeds, with potential for an additional $48.0 million from warrant exercises.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting personnel, lack of formal risk assessment, and inadequate controls over significant accounts and IT systems.
• Research and development expenses increased by 22.7% to $12.5 million in 2025, primarily due to the progression of the Acclaim CI clinical trial.
• Net revenues remained limited at $0.24 million in 2025, primarily from the legacy Esteem FI-AMEI product, which faces commercial challenges due to lack of reimbursement coverage.
• The Acclaim CI received Breakthrough Device Designation from the FDA in 2019, which may expedite development and review but does not guarantee approval or accelerated timeline.
• The company regained compliance with Nasdaq's market value of listed securities requirement on February 23, 2026, but remains subject to a one-year monitoring period.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging financial situation, marked by persistent losses and a going concern warning, despite the significant clinical progress of its lead product and recent capital infusion. The material weaknesses in internal controls add to the operational risk.

Positives

• Completed enrollment of all 56 patients in the pivotal clinical study for the Acclaim CI on March 10, 2026, a significant milestone in product development.
• The Acclaim CI received Breakthrough Device Designation from the U.S. FDA in 2019, potentially expediting its development and review process.
• Successfully raised approximately $27.7 million in net proceeds from a public offering in February 2026, providing capital for ongoing operations and clinical trials.
• Potential for an additional $48.0 million in gross proceeds from the full exercise of Series A-1 and Series A-2 Warrants issued in the February 2026 Offering.
• Regained compliance with Nasdaq's market value of listed securities requirement on February 23, 2026, maintaining its listing.
• The Acclaim CI is designed to be the first fully implanted cochlear implant, offering potential advantages over partially implanted devices such as increased daily usage, hearing at night, and use in water.
• The company holds rights to 40 issued U.S. patents and 48 issued foreign patents, protecting its core technology and future product concepts.
• The Esteem FI-AMEI, though commercially challenged, has over two decades of experience with its implantable sensor technology, proving its viability.

Negatives

• Reported a net loss of $23.8 million for 2025, an increase from $20.8 million in 2024, indicating continued unprofitability.
• Accumulated deficit grew to $313.4 million as of December 31, 2025, highlighting significant historical losses.
• The independent registered accounting firm expressed substantial doubt about the company's ability to continue as a going concern.
• Identified material weaknesses in internal control over financial reporting, including insufficient accounting personnel and lack of formal risk assessment, which could lead to material misstatements.
• Cash balance decreased to $3.7 million as of December 31, 2025, from $5.5 million in 2024, before the February 2026 offering.
• Revenue from product sales remains limited ($0.24 million in 2025) and is not expected to be significant until Acclaim CI commercialization.
• The Esteem FI-AMEI failed to gain commercial traction primarily due to CMS classification as a hearing aid, limiting reimbursement.
• The company is highly dependent on the successful commercialization of the Acclaim CI, with no other product candidates expected to generate significant revenue in the near future.
• The market price of Class A Common Stock has been and may continue to be extremely volatile, with significant fluctuations observed.

Risks

• Unpredictability in the medical device industry, regulatory approval process, and clinical development of products.
• Potential need for design changes to products to meet safety and efficacy endpoints.
• Changes in federal or state reimbursement policies that could adversely affect product sales.
• Introduction of other scientific advancements (e.g., gene therapy, pharmaceuticals) that may impact the need for hearing devices.
• Intense competition in the medical device industry and failure to introduce new products in a timely manner or at competitive prices.
• Disruptions in relationships with suppliers or in internal production capabilities for key components.
• Need for substantial additional funding, which may not be available on acceptable terms or at all, leading to curtailment or discontinuation of product development.
• Raising additional capital would cause dilution to existing stockholders and may adversely affect their rights.
• Failure of a key information technology system, process, or site could have an adverse effect on the business.
• Inability to remediate identified material weaknesses in internal control over financial reporting, or identification of additional weaknesses.
• The explanatory paragraph regarding substantial doubt about the ability to continue as a going concern could prevent obtaining new financing.
• Clinical failure can occur at any stage of development, and current clinical experience does not guarantee future favorable results or regulatory approval.
• Successful commercialization of Acclaim CI depends on establishing coverage, adequate reimbursement levels, and favorable pricing policies.
• Inability to successfully commercialize Acclaim CI or any subsequent decline in demand could severely harm revenue generation.
• Healthcare professionals may not recommend Acclaim CI, hindering market acceptance and profitability.
• Dependence on contract manufacturing organizations and material suppliers, leading to vulnerability to supply shortages, increased costs, and quality issues.
• Assumptions about the addressable market for Acclaim CI may be incorrect, and the company may not capture estimated market share.
• Dependence on third parties to manage pre-clinical studies and clinical trials, leading to potential costs and delays beyond control.
• High dependency on key members of the executive management team; inability to retain them could impede business plan and growth strategies.
• The market price of Class A Common Stock and Public Warrants has been and may continue to be extremely volatile.
• No intention to pay dividends on Class A Common Stock for the foreseeable future, except for Series A Preferred Stock.
• Potential for future securities litigation, which is expensive and could divert management attention.
• Failure to meet Nasdaq's continued listing requirements could result in delisting.
• Inability to obtain significant patent protection or inadequate protection of intellectual property rights.
• Potential for lawsuits or administrative proceedings involving patents or other intellectual property, leading to significant damages or cessation of product sales.
• Patent terms may not be sufficient to effectively protect products for an adequate period.
• Inability to enforce intellectual property rights throughout the world.
• Claims of misappropriation of third-party intellectual property or breach of non-competition agreements.
• Unfavorable global economic conditions, including inflation and interest rate increases, could adversely affect business and ability to raise capital.
• The company is an early-stage company with limited operating history and experience in rapidly evolving fields.

Future Outlook

The company anticipates obtaining FDA approval for the Acclaim CI in late 2027 or early 2028, assuming a successful pivotal clinical study and FDA review without a panel review. If a panel review is requested, the decision could extend to the first half of 2028. The commercialization strategy involves carefully selecting approximately 30 initial surgical sites, expanding by an additional 30 sites annually until reaching around 150 active implanting sites. International expansion, starting with the CE Mark in the European Union, is planned shortly after FDA approval, followed by other markets like Australia, Brazil, and parts of Asia. Research and development will focus on improving the existing Acclaim CI design, quality, reliability, and developing robust software and user interfaces.

Management Comments

• "We are a hearing health company focused on providing innovative medical technologies across the hearing loss spectrum."
• "We believe leveraging the ears natural anatomy, rather than external or sub-dermal artificial microphone, is the ideal way for people to hear."
• "We now believe we have the possibility to disrupt the cochlear implant market currently dominated by three main incumbents."
• "We believe that the Acclaim CI will be able to offer hearing benefit over the patients baseline condition and may also offer other important advantages over alternative hearing loss treatments."
• "We believe that the fully implanted nature of the Acclaim CI will facilitate an increase in daily usage over other types of cochlear implants because the device can be used 24-hours a day."
• "We believe that the Acclaim CI, with no externally worn components, may help reduce or perhaps even eliminate such stigma."
• "We believe a fully implanted cochlear implant could reduce cochlear implant costs over time by eliminating costly external components that are frequently replaced."
• "We believe that the initial results of the EFS were primarily promising. All EFS subjects have achieved hearing percepts through activation of the implant stimulator and achieve unique pitch percepts on each electrode, typical of all other cochlear implant recipients."
• "We are intrigued by the possibility of offering a fully implanted cochlear implant that could also allow for the use of a hearing aid or other ear accessory (e.g., ear buds) because the Acclaim CI leverages the ear to pick up sound."
• "Our commercialization strategy will be quality over quantity to facilitate the Acclaim CI gaining a meaningful foothold in the marketplace without unnecessary complications stemming from attempting to grow too quickly."
• "It is not only important for the market to know we support our patients for life, but it is the right thing to do for the patients."
• "Management believes that its existing cash balances combined with the initial proceeds of the February 2026 Offering and cash receipts from product sales will be sufficient to fund ongoing operations, including the Acclaim CI clinical trials, through at least one year from the date the consolidated financial statements are issued."

Industry Context

StockSavvy.ai notes that Envoy Medical operates in the highly competitive and concentrated hearing health market, particularly the cochlear implant segment, which is currently dominated by three major players: Cochlear Ltd., Advanced Bionics (Sonova), and Med-El. The industry trend is shifting towards enhanced usability, connectivity, lifestyle integration, and miniaturization of devices, alongside loosening clinical candidacy requirements to expand the addressable market. Envoy Medical's fully implanted Acclaim CI aims to disrupt this market by addressing the stigma and practical limitations of external components, potentially increasing market penetration beyond the current 5-8% for adults. However, the company faces the challenge of establishing distribution channels and physician relationships against entrenched competitors with significantly greater financial and operational resources.

Comparison to Industry Standards

• Envoy Medical's Acclaim CI aims to differentiate itself as the first fully implanted cochlear implant, contrasting with the partially implanted devices offered by industry leaders like Cochlear Ltd., Advanced Bionics (Sonova), and Med-El.
• Cochlear Ltd. holds approximately 65% of the global cochlear implant market share and had a market capitalization of approximately $12 billion USD as of December 31, 2025, significantly dwarfing Envoy Medical's current market presence and financial resources.
• The estimated adult cochlear implant market in the United States alone is over $80 billion, with an annual market opportunity exceeding $750 million by 2026, suggesting substantial room for growth if Envoy Medical can capture market share from incumbents and the unserved market.
• Current market penetration for cochlear implants in the adult population is estimated at 5-8%, indicating a large untapped market that Envoy Medical's fully implanted solution could potentially address by reducing stigma and improving user experience.
• Unlike the Esteem FI-AMEI, which was classified as a hearing aid and lacked Medicare/Medicaid coverage, the Acclaim CI is expected to be eligible for coverage as a cochlear implant, aligning with the established reimbursement pathways enjoyed by competitors' devices.

Management Changes

Corporate Governance

Legal Proceedings

• On November 14, 2023, Atlas Merchant Capital SPAC Fund I LP (Atlas) filed a complaint in the Delaware Court of Chancery against the company, Whitney Haring-Smith (former CEO), Daniel Hirsch (former CFO), and Anzu SPAC GP I LLC. Atlas alleges it was not allowed to redeem its shares of Anzu Class A common stock and seeks approximately $9.4 million in damages, interest, costs, and attorneys' fees. The company believes the lawsuit is meritless and is vigorously defending it.
• On March 3, 2025, the court partially granted a motion to dismiss in the Atlas lawsuit, narrowing the scope of the litigation.

Related Party Transactions

• The company leases its headquarters office space in Minnesota from a stockholder (Glen A. Taylor), which is considered a related party. The lease was modified in 2024 and 2025 to extend the term and increase office space.
• Received Term Loans from GAT Funding, LLC (an entity controlled by Glen A. Taylor) during 2024 and 2025, totaling $30 million in principal. These loans were extinguished on August 25, 2025, with GAT forgiving outstanding principal and accrued interest in exchange for a $100,000 payment.
• Has a shared services arrangement with a company indirectly owned by the stockholder (Taylor Technology Services, Inc.) for IT services, with immaterial expenses.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from outstanding warrants and potential future equity offerings. The stock price has been highly volatile, and the going concern warning poses a substantial risk to investment value. No cash dividends are anticipated on Class A Common Stock for the foreseeable future.
• **Employees:** The company is hiring additional accounting and financial reporting personnel as part of remediation efforts for material weaknesses, potentially creating new opportunities. Employee compensation has increased since 2022 to aid retention and attract new talent.
• **Customers/Patients:** Potential for a breakthrough fully implanted cochlear implant (Acclaim CI) could offer improved access, usability, independence, and quality of life for individuals with severe-to-profound hearing loss. However, commercialization is contingent on FDA approval and establishing reimbursement.
• **Creditors:** The extinguishment of Term Loans from a related party (GAT Funding, LLC) involved forgiveness of significant debt, which could be viewed positively by other creditors, but the overall going concern status remains a concern.
• **Suppliers:** The company relies on a limited number of third-party suppliers for critical sub-assemblies, making it vulnerable to supply shortages and increased costs, which could impact production and commercialization timelines.

Next Steps

• Collect and analyze 12-month follow-up data for all 56 patients in the Acclaim CI pivotal clinical study.
• Submit a Premarket Approval (PMA) application to the FDA for the Acclaim CI.
• Await FDA decision on the PMA application, anticipated in late 2027 or early 2028.
• Establish a commercialization strategy focusing on training approximately 30 initial surgical sites, expanding by 30 sites annually.
• Pursue Conformit Europenne mark (CE Mark) in the European Union shortly after FDA approval for international commercialization.
• Address and remediate identified material weaknesses in internal control over financial reporting, including hiring additional accounting personnel and implementing formal risk assessments.
• Continue research and development to improve the existing Acclaim CI design, quality, reliability, and software/user interfaces.
• Potentially pursue other international markets such as Australia, Brazil, and parts of Asia based on market size and reimbursement availability.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, evidenced by a significant accumulated deficit of $313.4 million and recurring net losses. While the completion of the Acclaim CI pivotal clinical trial and a recent capital raise provide some positive momentum, the inherent risks of regulatory approval (anticipated late 2027/early 2028), intense competition, and identified material weaknesses in internal controls present a highly speculative investment profile. The volatility of the stock price and the lack of near-term profitability further underscore the precarious financial position. A seasoned investor would likely view the long-term viability as highly uncertain, making a 'sell' recommendation prudent to mitigate exposure to these significant risks.

Keywords

Cochlear Implant, Hearing Loss, Medical Device, FDA Approval, Clinical Trial, Sensorineural Hearing Loss, Fully Implanted, Breakthrough Device Designation, SEC Filing, 10-K, Financial Reporting, Corporate Governance, Risk Factors, Capital Raise, Nasdaq Listing, Intellectual Property, Biotechnology, Healthcare Technology